Anti-RSV gpF therapeutic antibody (Pre-made Suptavumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Suptavumab (INN; development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-535-1mg	1mg	3090
GMP-Bios-ab-535-10mg	10mg	21890
GMP-Bios-ab-535-100mg	100mg	148000
GMP-Bios-ab-535-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-RSV gpF therapeutic antibody (Pre-made Suptavumab biosimilar,Whole mAb)
INN Name	Suptavumab
Target	RSV gpF
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Regeneron Pharmaceuticals
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Respiratory syncytial virus infections
Development Tech	VelocImmune Mouse;VelociGene